Sugi Predict

Sugi Predict / Compounds / SCHEMBL3916889

SCHEMBL3916889

SCHEMBL3916889

CCC1(CC)CC2(CC(C)(C)N1[O])OCC(COCc1ccccc1)O2

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ TMEM97 Q5BJF2 3/20 0.36
▸ SIGMAR1 Q99720 3/20 0.36
▸ TAAR1 Q96RJ0 1/20 0.35
▸ PTPN1 P18031 2/20 0.35
▸ HTR1A P08908 2/20 0.34
▸ CDC25B P30305 1/20 0.34
▸ ADRA1D P25100 1/20 0.34
▸ ADRA1A P35348 1/20 0.34
▸ ADRA1B P35368 1/20 0.34
▸ POLB P06746 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ HRH4 Q9H3N8 4/20 0.33
▸ HRH3 Q9Y5N1 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4989283 0.82 L3MBTL1 (0.32) LMNAL3MBTL1TMEM97SIGMAR1PTPN1
SCHEMBL11449211 0.80 L3MBTL1 (0.32) LMNAL3MBTL1TMEM97SIGMAR1
SCHEMBL3930163 0.80 CA2 (0.31) —
SCHEMBL3927061 0.78 GAA (0.31) —
SCHEMBL11459437 0.78 LMNA (0.43) LMNAL3MBTL1TMEM97SIGMAR1TAAR1
SCHEMBL3918656 0.78 TACR1 (0.31) LMNA
SCHEMBL13715865 0.76 LMNA (0.34) LMNAL3MBTL1TMEM97SIGMAR1TAAR1
SCHEMBL975131 0.76 TDP1 (0.34) LMNAHTT
SCHEMBL3924081 0.75 — —
SCHEMBL3919511 0.75 HSP90AA1 (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572869-B2 N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith CIBA SPECIALTY CHEMICALS CORP. (US) 2009-08-11 — — US claimed
US-20080015276-A1 N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith NESVADBA PETER 2008-01-17 — — US claimed
US-20040082742-A1 N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith CIBA SPECIALTY CHEMICALS CORP. 2004-04-29 — — US claimed
EP-1343827-A1 N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, THEIR CORRESPONDING N-OXIDES AND CONTROLLED RADICAL POLYMERIZATION THEREWITH Ciba SC Holding AG (CH) 2003-09-17 — — EP claimed
WO-2002048205-A1 N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, THEIR CORRESPONDING N-OXIDES AND CONTROLLED RADICAL POLYMERIZATION THEREWITH CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-06-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015276-A1 N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith ALKBH2, ALKBH3, ALKBH5 LMNA 1246/4885L3MBTL1 3335/4885TMEM97 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.